World market for cancer vaccines 2007-2012

"Lung cancer vaccine to be tested"

"New US bill requires cancer vaccine for girls"

"Cancer vaccine too expensive"

These are just some of the news headlines that have seen the world cancer vaccine market turned on its head. The benefits are unquestionable, the costs of the drugs however may yet see take-up slow. How will this effect your company? This report will tell you.

There are two types of cancer vaccines:

> Prophylactic cancer vaccines, designed to prevent the development of cancer, they are given to healthy subjects to prevent infection with cancer-causing viruses

> Therapeutic cancer vaccines, designed to treat existing cancers, they are given to cancer patients to stimulate the immune system into recognising and destroying their existing cancer

Previously the cancer vaccine market has consisted of HBV (hepatitis B virus) vaccines to prevent liver cancer. 2006 saw the launch of Gardasil the first vaccine against HPV (human papilloma virus) to protect against cervical cancer. Another HPV vaccine, Cervarix, is due to be launched in 2007. These two vaccines are together predicted to generate sales of more than $4bn in 2012, which could see them becoming the top selling vaccines. Their success could lead a growth in the cancer vaccines market, resulting in it being worth 7 times what it is today. Will you be able to capture your share of the market place?

Therapeutic cancer vaccines, designed to stimulate the immune system into killing existing cancers, also look likely to soon achieve commercial success, after much investment into their research and development. The first therapeutic cancer vaccine is expected to be launched in 2007, with a number of others predicted to obtain licenses in the next few years. Hw will this effect current cancer drugs and treatments? Understand today.

The report gives an overview of the current and potential market for cancer vaccines, in particular concentrating on the following aspects of cancer vaccines:

> Technologies utilised by cancer vaccines

> Key players in cancer vaccines

> Revenue forecasts for prophylactic cancer vaccines

> Therapeutic cancer vaccines likely to achieve commercial success

> Drivers and opportunities in the cancer vaccine market

> Restraints and threats in the cancer vaccine market

> The cancer vaccine pipeline

> Why you must by this report:

The pharmaceutical industry has been seeking the next blockbuster drug, yet it appears as though these might not be as profligate as they have been in the past. However, the addiction treatment markets hold promise, particularly for the development of products for nicotine addiction and the treatment of obesity. This report analyses the current situation in the market and assesses the potential of the products that are currently in the development pipeline. A comprehensive analysis of the addiction treatment market from 2006-2011 outlines the potential of the market. Visiongain expects to see the development of at least two multi-billion dollar markets. You and your company should be part of this market, and you could be by placing your order immediately.

Unique benefits to you when you order this report:

- Full searchable report when you buy the company or corporate editions

- Immediate access through our exclusive Reading Room

- You can access your report whichever country you are in without using harddrive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

Organizations listed:

Aarstrom Biosciences Inc.

Acorda Therapeutics

Advanced BioHealing, Inc.

Advanced Cell Technology Inc.

Aldagen, Inc.

American Society of Plastic Surgeons

Amersham

Amgen

Angel BioTechnology

Ansary Center for Stem Cell Therapeutics

Arthritis Research Campaign, UK

AstraZeneca

Athersys

Axordia

Bart’s and The London NHS Trust, UK

BioE

Bioheart, Inc.

Biotechnology and Biological Sciences Research Council, UK

BrainStorm Cell Therapeutics

BresaGen

Burnham Institute for Medical Research

The California Family Bioethics Council

California Institute for Regenerative Medicine

Cellartis

CellCura

Cellerant

Cellular Dynamics International

The Cellulite Clinic

Center for Stem Cell and Regenerative Medicine, Ohio

Cordlife

Cythera/ Novocell

Cytori Therapeutics

Department of Health and Human Services, US

Epistem

ES Cell International (ESI)

European Patent Office

Fisher

Food and Drug Administration, US

Gamida

Genentech

Genzyme

Geron

GlobalStem Inc

Human Fertilisation and Embryology Authority, UK

Illinois Regenerative Medicine Institute

Institute for Regenerative Medicine

Intercytex

Invitrogen

The Joan and Sanford I Weill Medical Centre

Johns Hopkins University

Johnson and Johnson

Juvenile Diabetes Research Foundation

King’s College, London

Maryland Technology Development Corporation

Mediatech Inc

Medical Research Council, UK

Medra Clinic

Memorial Sloan-Kettering Cancer Centre

Merck

Mesoblast Limited

Nabi Medspa

The National Academies, US

The National Institutes of Health, US

National Health Service

National Science Foundation

National Tax Limitation Committee

Neuronova

New Jersey Stem Cell Institute

Novartis AG

Novathera

Novocell

Odontis

Organogenesis

Osiris

Pluristem

RegenTec

Reinnervate

Reliance Life Sciences

ReNeuron

Renovo

RhinoCyte, Inc.

Rockefeller University

Roslin Institute

Royal College of Obstetrics and Gynaecologists, UK

Schering AG

Sigma-Aldrich

Smith and Nephew

The Starr Foundation

Stem Cells Inc.

Stem Cell Innovations

StemCell Technologies Inc.

Stem Cell Therapeutics Corp

Stem Cell Sciences

StemCo Biomedical

Stempeutics

Tengion

TheraVitae

Titan Pharmaceuticals Inc.

Tulane University

UK Stem Cell Bank

United States Patents and Trademark Office

University of Maryland

University of Massachusetts

University of Newcastle

University of San Francisco, California

University of Texas Health Centre

University of Wisconsin

Vesta Therapeutics Inc.

Viacell

Vistagen Therapeutics Inc.

Wellcome Trust, UK

WiCell Research Institute, US

Wisconsin Alumni Research Foundation

Wisconsin State Laboratory of Hygiene

Wolfson Foundation, UK

World Health Organisation

Lead Analyst: Debra Scates Publication Date: 17/01/07 Pages: 90

Single user licence: The Report is delivered via an on-line reading room. One use access only, the report is in Flash format in a printable format.

Department: Report is delivered via an on line reading room. Five user access only, the report is in Flash format in a printable format.

Company/site wide licence: The report is delivered in email format as a PDF document with no locking system attached. The report can be loaded onto the company's intranet site.
Table of Contents

Price
Single User Licence $3998.00
Department Licence 5 Users $7998.00
Company-wide Intranet Licence $13,998.00